5 Reasons To Buy Clinuvel Pharmaceuticals After Its Nasdaq Uplisting

Clinuvel Pharmaceuticals Limited is a profitable orphan-drug biotech with SCENESSE driving over 90% of revenue and exceptional margins. Despite flat growth in FY2026, CUVL maintains a strong balance sheet with A$252.1M in cash and no debt, funding expansion and R&D internally. The upcoming CUV105 vitiligo trial is a major catalyst; success could transform CUVL's scale, but competition from AbbVie and Pfizer intensifies the risk.